NDA 018304 · Fresenius Kabi USA
Sensorcaine
Bupivacaine Hydrochloride, Epinephrine Bitartrate · Injection
Last checked: Nov 20, 2026Latest source record: Jul 19, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1981
Dec 30, 1981
Approved uses
1
Original approval plus efficacy supplements
Registered trials
2,836
341 Phase 3, 228 recruiting
FAERS reports
2,545
1,664 serious, 231 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 9, 2026.
INDICATIONS & USAGE Sensorcaine (bupivacaine HCl) is indicated for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures. Only the 0.25% and 0.5% concentrations are indicated for obstetrical anesthesia (see WARNINGS). Experience with nonobstetrical surgical procedures in pregnant patients is not sufficient to recommend use of the 0.75% concentration of bupivacaine HCl in these patients. Sensorcaine is not recommended for intravenous regional anesthesia (Bier Block) (see WARNINGS). The routes of administration and indicated Sensorcaine concentrations are: Standard textbooks should be consulted to determine the accepted procedures and techniques for the administration of Sensorcaine. Table1.jpg
Therapeutic areas: Kidney and urology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 30, 1981 Original approval
5 products under this application
- SENSORCAINE · BUPIVACAINE HYDROCHLORIDE 0.75%; EPINEPHRINE BITARTRATE 0.0091MG/ML · INJECTABLE, INJECTION · Prescription · TE AP
- SENSORCAINE · BUPIVACAINE HYDROCHLORIDE 0.75% · INJECTABLE, INJECTION · Prescription · TE AP
- SENSORCAINE · BUPIVACAINE HYDROCHLORIDE 0.25% · INJECTABLE, INJECTION · Prescription · TE AP
- SENSORCAINE · BUPIVACAINE HYDROCHLORIDE 0.5%; EPINEPHRINE BITARTRATE 0.0091MG/ML · INJECTABLE, INJECTION · Prescription · TE AP
- SENSORCAINE · BUPIVACAINE HYDROCHLORIDE 0.5% · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Bupivacaine" as an intervention, any sponsor and status, largest first.
Vanderbilt University Medical CenterAcademic, hospital or other
NCT02726620 · 22,435 participants · Start Jan 5, 2017 · Primary completion Dec 31, 2017
Drug: Propofol; Sevoflurane and 32 more · For: Hypotension
Sites: Nashville, Tennessee
- Perioperative Multimodal Analgesia Protocol for Supratentorial CraniotomyPivotal-lookingNot yet recruiting
Beijing Tiantan HospitalAcademic, hospital or other
NCT06406829 · 2,000 participants (planned) · Start Feb 9, 2026 · Primary completion Dec 31, 2026
Drug: Dexmedetomidine; Normal saline · For: Postoperative Pain; Analgesia; Supratentorial Brain Tumor
- Perioperative Multimodal Analgesia for Supratentorial CraniotomyPivotal-lookingRecruiting
Beijing Tiantan HospitalAcademic, hospital or other
NCT07441421 · 2,000 participants (planned) · Start Mar 9, 2026 · Primary completion Dec 31, 2027
Drug: Dexmedetomidine · For: Postoperative Pain; Analgesia; Supratentorial Brain Tumor
Sites: Beijing, China
- A Sequenced Strategy for Improving Outcomes in People With Knee Osteoarthritis PainPivotal-lookingCompleted
Johns Hopkins UniversityAcademic, hospital or other
NCT04504812 · 1,937 participants · Start Feb 1, 2021 · Primary completion Apr 8, 2025
Drug: Duloxetine · For: Knee Osteoarthritis
Sites: Sacramento, California; San Diego, California; Aurora, Colorado · 24 sites in all
- Anesthesia and Perioperative Neurocognitive Disorders in the Elderly Patients Undergoing Hip Fracture Surgery Platform Trial (ANDES Platform Trial)Pivotal-lookingRecruiting
Second Affiliated Hospital of Wenzhou Medical UniversityAcademic, hospital or other
NCT06452147 · 1,860 participants (planned) · Start Jun 19, 2024 · Primary completion Jul 30, 2028
Drug: Bupivacaine liposome; Regular local anesthetic and 1 more · For: Anesthesia; Hip Fractures; Dementia and 2 more
Sites: Dongyang, China; Hangzhou, China; Jinhua, China · 13 sites in all
- Catheter Outcomes With Sternotomy Cardiac OperatedPivotal-lookingCompleted
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT01648777 · 1,502 participants · Start Mar 2012 · Primary completion Jan 2015
Drug: placebo · For: Pneumonia; Cardiac Surgery; Multiperforated Catheter and 2 more
Sites: Paris, France
- Efficacy and Safety of Intrathecal Morphine for Postoperative Pain Management Following Planned Caesarean SectionPivotal-lookingRecruiting
Anne Juul WikkelsøAcademic, hospital or other
NCT06797973 · 1,312 participants (planned) · Start Jul 15, 2025 · Primary completion May 31, 2027
Drug: Intrathecal Morphine; Placebo (Sodium Chloride Injection, 0.9%) · For: Caesarean Section; Postoperative Pain
Sites: Aarhus, Denmark; Copenhagen, Denmark; Herlev, Denmark · 9 sites in all
- Combined Spinal-epidural Anesthesia for Cesarean Section Without Prophylactical Prehydration and VasopressorsPivotal-lookingStatus unknown
Shenzhen People's HospitalAcademic, hospital or other
NCT03497364 · 930 participants (planned) · Start May 1, 2018 · Primary completion Nov 30, 2021
Drug: bupivacaine; ropivacaine · For: Cesarean Section; Anesthesia, Spinal
Sites: Shenzhen, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective653
- anaesthetic complication215
- musculoskeletal pain202
- maternal exposure during pregnancy196
- off label use180
- hypoaesthesia152
- hypotension128
- condition aggravated126
- joint injury126
- dyspnoea122
- hypertension118
- headache114
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 20 |
| 2005 | 10 |
| 2006 | 30 |
| 2007 | 14 |
| 2008 | 28 |
| 2009 | 158 |
| 2010 | 78 |
| 2011 | 39 |
| 2012 | 37 |
| 2013 | 37 |
| 2014 | 28 |
| 2015 | 106 |
| 2016 | 283 |
| 2017 | 35 |
| 2018 | 78 |
| 2019 | 88 |
| 2020 | 107 |
| 2021 | 138 |
| 2022 | 255 |
| 2023 | 188 |
| 2024 | 275 |
| 2025 | 302 |
| 2026 | 211 |
Recalls
1 FDA enforcement reports for this application.
Dec 10, 2020 · Class II · Terminated
Subpotent Drug: Low out-of-specification assay results for the epinephrine component.
Shortages
FDA's drug shortage list.
Current · updated Nov 18, 2026
Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-31). Delay in shipping of the drug
Current · updated Nov 18, 2026
Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-17). Check wholesalers for inventory
Current · updated Nov 18, 2026
Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-465-57). Check wholesalers for inventory
Current · updated Nov 18, 2026
Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-31). Demand increase for the drug
Current · updated Nov 18, 2026
Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-31). Delay in shipping of the drug
Current · updated Nov 3, 2026
Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-37). Other
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Sensorcaine (Bupivacaine HCl)
2024 spending
$185
Beneficiaries
n/a
11 claims
Per beneficiary
n/a
$0.19 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $357 |
| 2021 | $462 |
| 2022 | $141 |
| 2023 | $369 |
| 2024 | $185 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Analgesic Effectiveness of Liposomal Bupivacaine versus Plain Local Anesthetics for Abdominal Fascial Plane Blocks: A Systematic Review and Meta-analysis of Randomized Trials.
Hussain N, Speer J, Abdallah FW · Anesthesiology 2024 · Meta-Analysis, Systematic Review
- Liposomal Bupivacaine, Plain Bupivacaine, and Saline for Transversus Abdominis Plane Blocks: The CLEVELAND Randomized Trial.
Turan A, Ali Sakr Esa W, Brooker J, et al. · Anesthesiology 2026 · Randomized Controlled Trial
- Addition of Liposomal Bupivacaine to Standard Bupivacaine versus Standard Bupivacaine Alone in the Supraclavicular Brachial Plexus Block: A Randomized Controlled Trial.
Chan TCW, Wong JSH, Wang F, et al. · Anesthesiology 2024 · Randomized Controlled Trial, Comparative Study
- Thermographic evaluation of the autonomic effects of nerve blocks in the foot.
Jacobs AM, Esper R, O'Leary R, et al. · J Am Podiatr Med Assoc 1989 · Clinical Trial, Randomized Controlled Trial
- Combined pectoralis and serratus anterior plane blocks with or without liposomal bupivacaine for minimally invasive thoracic surgery: A randomized clinical trial.
Marciniak D, Raymond D, Alfirevic A, et al. · J Clin Anesth 2024 · Randomized Controlled Trial
- Intrathecal anesthesia: ropivacaine versus bupivacaine.
Malinovsky JM, Charles F, Kick O, et al. · Anesth Analg 2000 · Clinical Trial, Comparative Study
Sponsor: Fresenius Kabi USA
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.